Medicine Man Technologies, Inc.
SHWZ$62M
Micro CapNASDAQServices-Management Consulting Services🇺🇸North AmericaDENVER
Drugs in Pipeline
8
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
SHWZ News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
NFC-1
Attention Deficit Disorder With Hyperactivity
AEVI-001
Attention Deficit Hyperactivity Disorder
CERC-002
COVID-19 Pneumonia
MDGN201 TARGTEPO
Chronic Kidney Disease
HMI-115-120mg-Q4W
Androgenetic Alopecia
HMI-115
Endometriosis
INS018_055
Idiopathic Pulmonary Fibrosis (IPF)
ISM5411 tablets
Ulcerative Colitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NFC-1 | Phase 3 | Attention Deficit Disorder With Hyperactivity | - | - |
AEVI-001 | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
CERC-002 | Phase 2 | COVID-19 Pneumonia | - | - |
MDGN201 TARGTEPO | Phase 2 | Chronic Kidney Disease | - | - |
HMI-115-120mg-Q4W | Phase 2 | Androgenetic Alopecia | - | - |
HMI-115 | Phase 2 | Endometriosis | - | - |
INS018_055 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | - | - |
ISM5411 tablets | Phase 2 | Ulcerative Colitis | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply